Roy Baynes, MB.BCh., M.Med., Ph.D., FCP, FACP
Roy Baynes has served as a member of our board of directors since July 2018. Dr. Baynes is Chief Medical Officer at Merck, and Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories. Dr. Baynes was previously Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at Gilead Sciences, and also served as Vice President of Global Clinical Development and Therapeutic Area Head for Hematology/Oncology at Amgen. Dr. Baynes has had a long and distinguished career in the hematology, oncology, and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching, and administration. He is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research, and has authored about 150 publications. Before joining industry in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center. Dr. Baynes graduated as a medical doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand in Johannesburg, South Africa.
Monica Bertagnolli, M.D.
Roelof F. Botha
Roelof F. Botha has served as a member of our board of directors since 2007. Mr. Botha has been with Sequoia Capital, a venture capital firm, since 2003, and has been a Managing Member of Sequoia Capital Operations, LLC since 2007.From 2000 to 2003, Mr. Botha served in a number of roles at PayPal, Inc., most recently as the Chief Financial Officer. From 1996 to 1998, Mr. Botha served as a management consultant for McKinsey & Company, a management consulting firm. Mr. Botha currently serves on the board of directors of Square, Inc. (NYSE: SQ), a provider of payments, financial and marketing services; MongoDB, Inc. (Nasdaq: MDB), a document oriented database program developer; Eventbrite, Inc. (NYSE: EB), an event management and ticketing platform; Unity, Inc. (NYSE: U), a 3D and VR content development platform, and a number of private companies. Mr. Botha holds a Bachelor of Science in Actuarial Science, Economics, and Statistics from the University of Cape Town and an M.B.A. from Stanford University.
Rowan Chapman, Ph.D.
Rowan Chapman has served as a member of our board of directors since August 2019. Dr. Chapman is a founder, investor, and active independent board member. She most recently held senior roles as Head of Johnson & Johnson Innovation, Western North America, Australia and New Zealand, and as Head of Precision Diagnostics at GE Healthcare Life Sciences, Managing Director of New Business Creation, and Head of Healthcare Investing at GE Ventures. Prior to that, she held operational roles in early and growth-stage startups and was a partner at Mohr Davidow Ventures for over 11 years, gaining extensive experience as a board member and board advisor for a wide variety of tech and data-enabled companies. Dr. Chapman holds a Bachelor of Arts degree in Biochemistry and a Doctor of Philosophy degree in Biochemistry and Molecular Biology from the University of Cambridge, United Kingdom.
Steve Chapman has served as the Company’s Chief Executive Officer, and as a director on its board of directors, since January 2019. Previously, Mr. Chapman served as the company’s Chief Operating Officer from August 2017 to January 2019, and Chief Commercial Officer from March 2017 to August 2017. Mr. Chapman began working at Natera, Inc. in December 2010 and held positions including the Vice President of Sales and Vice President, Commercial Operations. Mr. Chapman worked previously at Genzyme Genetics Corp., a biotechnology company, from 2003 to 2010. Mr. Chapman holds a Bachelor of Science in Microbiology, Immunology and Molecular Genetics from University of California, Los Angeles.
Todd Cozzens has served as a member of our board of directors since 2011. Mr. Cozzens has been with Sequoia Capital, a venture capital firm, since 2012. From 2010 to 2012, Mr. Cozzens served as Chief Executive Officer of Optum Accountable Care Solutions, a business unit of Optum/United Healthcare Group. From 2000 to 2010, Mr. Cozzens served as Chief Executive Officer of Picis Inc., a provider of electronic medical record software to hospitals, until its acquisition by the UnitedHealth Group in 2010. Mr. Cozzens currently serves on the boards of directors of Health Catalyst, LLC and a number of privately held companies. Mr. Cozzens holds a Bachelor of Arts degree from Marquette University and completed the Program for Management Development at Harvard University.
James I. Healy, M.D., Ph.D.
James I. Healy has served as a member of our board of directors since November 2014. Dr. Healy has been a General Partner at Sofinnova Ventures, a venture capital firm, since 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, a venture capital firm, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories), a research-based pharmaceutical company and ISTA Pharmaceuticals, Inc., a company specializing in ophthalmic pharmaceutical products. Dr. Healy is currently on the board of directors of Ascendis Pharma A/S, a clinical-stage biopharmaceutical company, Amarin Corporation plc, a commercial-stage biopharmaceutical company, Auris Medical Holding AG, a specialty pharmaceutical company focused on tinnitus, Coherus BioSciences, Inc., a biologics platform company, and several private companies. Previously, Dr. Healy served as a board member of Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammation and autoimmune diseases, from 2006 to 2014; Durata Therapeutics, Inc., a pharmaceutical company focused on infectious and acute diseases, from 2009 to 2013; InterMune, Inc., a biotechnology company focused on orphan fibrotic pulmonary disease, from 1999 to 2014; KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of monoclonal antibody therapeutics, from 2001 to 2014; Hyperion Therapeutics, Inc., a commercial-stage orphan disease company, from 2007 to 2015 and several private companies. Dr. Healy holds an M.D. and Ph.D. in Immunology from Stanford University School of Medicine and performed neuroscience research at the University of Virginia School of Medicine. Dr. Healy holds a Bachelors of Arts in Molecular Biology and Scandinavian Studies from the University of California at Berkeley.
Gail Marcus, D.H.A.
Gail Marcus has served as a member of our board of directors since March 2017. Dr. Marcus is currently an Assistant Professor and Executive in Residence at the Massachusetts College of Pharmacy and Health Sciences. Prior to academia, Dr. Marcus was a healthcare executive across a diverse portfolio of healthcare organizations in the US and UK, including Cigna, UnitedHealthcare Group Inc., CVS/Caremark, and Caris Diagnostics of Caris Life Sciences. In 2014, she was selected as one of the top 100 women executives in Massachusetts. Dr. Marcus currently serves on the boards of directors of another public company, a private company and a non-profit organization, and sits on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests. Dr. Marcus holds aDoctorate of Health Administration from the Medical University of South Carolina. She received a B.A. in Spanish and Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School Of Engineering and a M.B.A. from the Wharton School of the University of Pennsylvania.
Matthew Rabinowitz, Ph.D.
Co-founder and Executive Chairman of the Board
Matthew Rabinowitz is a co-founder of our company and currently serves as our Executive Chairman. Dr. Rabinowitz served as our Chief Executive Officer from 2005 to January 2019 and served as a member of our board of directors since 2005. He served as Chairman of our board of directors from May 2015 to January 2019, at which time he assumed the role of Executive Chairman. Prior to co-founding our company, Dr. Rabinowitz served from 2000 to 2003 as chief executive officer and from 2003 to 2007 as chief technology officer of Rosum Corporation, a location services technology company. Dr. Rabinowitz served as a consulting professor at Stanford University from 2004 to 2012 and as visiting faculty in the Genetics Department of Harvard University from 2018 to 2019. Dr. Rabinowitz has over 100 patents and publications in signal processing, machine learning, bio-informatics, and high-throughput genetic testing. He received the Scott Helt Memorial Award from the Institute of Electrical and Electronics Engineers and has twice received the Technology Pioneer Award from the World Economic Forum. He currently serves as a member of the board of directors or advisory board of a number of technology companies. Dr. Rabinowitz holds a Bachelor of Science degree in Engineering and Physics, a Master of Science in Electrical Engineering, and a Ph.D. in Electrical Engineering, from Stanford University.
Herm Rosenman served as our Chief Financial Officer from February 2014 to January 2017, and has served as a member of our board of directors since February 2017. Prior to joining our company, he held the position of Senior Vice President—Finance and Chief Financial Officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood, from June 2001 to April 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Prior to joining Gen-Probe, he was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. Mr. Rosenman has served on the board of directors of Oxford Immunotec Global PLC, a commercial stage diagnostics company, since2013. Mr. Rosenman served on the board of directors of Medistem, Inc., a stem cell therapy company, from 2013 to2014; ARYx Therapeutics Inc., a private drug discovery and development company, from 2006 to 2009; Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chairman of the Audit Committee, from 2003 to 2007. He has also served on the board of directors of a number of privately held companies. Mr. Rosenman holds a B.B.A. in accounting and finance from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.
Co-founder and Director
Jonathan Sheena is a co-founder of our company. Mr. Sheena has served as a member of our board of directors since 2007, and served as our Chief Technology Officer from 2007 to December 2020. In 1999, Mr. Sheena co-founded PhoneSpots, Inc. (formerly PocketThis, Inc.), a mobile technology company serving mobile carriers worldwide. From June1999 to December 2007, Mr. Sheena held various roles at PhoneSpots, Inc. including vice president of product management and chief technology officer. Mr. Sheena holds a Bachelor of Science in Electrical Engineering and Computer Science, and a Master of Engineering in Electrical Engineering and Computer Science, from the Massachusetts Institute of Technology.